Opinion|Videos|January 1, 2025
Patient and Therapy Considerations Guiding Initiation of Treatment in RET-Positive NSCLC
Author(s)Heather A. Wakelee, MD, FASCO, Jacob Sands, MD
Panelists discuss their initial impressions of a patient case with RET fusion–positive non–small cell lung cancer (NSCLC), treatment goals for newly diagnosed patients, and the key patient and disease characteristics considered when selecting a first-line treatment regimen.
Advertisement
Episodes in this series
- Dr Sands to Dr Wakelee: What are your initial impressions of this case? How might you have treated this patient in your practice?
- Dr Wakelee to Dr Sands: What are your treatment goals for patients newly diagnosed with RET fusion–positive NSCLC?
- Dr Sands: Describe which patient and disease characteristics you consider when selecting a first-line treatment regimen.
Advertisement
Related to this article
First results from the phase 2 AZUR-1 trial showed sustained clinical complete responses with dostarlimab alone, sparing most patients chemoradiation and surgery.
The FDA approved talazoparib plus enzalutamide in HRR-mutated prostate cancer, ivonescimab improved survival in biliary tract cancer, and more.
P. Leia Nghiemphu, MD, discusses INTUITT-NF2 trial findings, the NCCN inclusion of brigatinib, and unmet needs in NF2-related schwannomatosis.
NEXERA-303 is evaluating INCA33890 plus FOLFOX and bevacizumab vs chemotherapy and bevacizumab alone in previously untreated MSS mCRC.
Biagio Ricciuti, MD, PhD, discusses Krascendo 1 data for divarasib, co-mutation–guided sequencing, and emerging RAS inhibitors in KRAS G12C–positive NSCLC.
Fox Chase researchers identified ANO6 as a potential pancreatic cancer target; blocking it slowed tumor growth and reduced immune suppression in preclinical studies.
Davide Melisi, MD, PhD, discusses INCB161734’s mechanism of action and the DAWN-303 trial design in KRAS G12D-mutated pancreatic cancer.
Breakthroughs with daraxonrasib in pancreatic cancer pave the way for continued investment in understanding the fundamental biology of cancers.
Advertisement
Advertisement
Trending on OncLive
1
INCB161734 Combination Data Shape DAWN-303’s All-Comers Design in Frontline KRAS G12D-Mutated PDAC
2
Krascendo 1 Survival Data Position Divarasib to Reset Second-Line Standards and Fuel First-Line Combinations in KRAS G12C–Mutated NSCLC
3
Fox Chase Cancer Center Researchers Identify Potential New Target for Pancreatic Cancer
4
Perioperative Research Success Is Set to Transform Bladder Cancer Care After ESMO 2026
5